Chagas Giovana Gomes, Pimenta Ruan, Viana Nayara Izabel
Department of Bioscience, Universidade do Estado de Minas Gerais-UEMG, Passos, MG 31630, Brazil.
Precision Immunology Institute, Department of Immunology and Immunotherapy, and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Oncol Res. 2025 May 29;33(6):1283-1288. doi: 10.32604/or.2025.055100. eCollection 2025.
The monoclonal antibodies consist of an innovative form of immunotherapy, capable of defeating several diseases, such as cancer. It is an emergent and important theme, that advances evaluation, challenges, and future perspectives with high relevance to identify gaps in recent studies and to consolidate this general theme in only one research. Its action in Chronic and Acute Lymphoid Leukemia has been evaluated in several clinical trials, which were selected between 2022 and 2023, in order to understand better the monoclonal antibodies that were most studied. The biopharmaceutical compounds Ibrutinib, Obinutuzumab, Rituximab, Venetoclax, and Inotuzumab Ozogamicin were the ones that most appeared in the most recent publications, indicating the importance of amplifying the studies. The action mechanisms that are used imply that their combined use has more success in the disease remission, showing a lower recurrence, adverse effects, and toxicity. Besides the adverse effects and overwhelming prices of the treatment, these immunotherapies results are promising, amplifying the survival rates, improving the patient's life quality, and resulting in a precision medicine, aiming a custom treatment. The future perspectives on this therapy consist of its application in the public health system, with patients being able to be submitted to this treatment without any costs and receive a better life quality.
单克隆抗体是一种创新的免疫疗法形式，能够战胜多种疾病，如癌症。这是一个新兴且重要的主题，它推进了评估、挑战以及未来展望，这些与识别近期研究中的差距高度相关，并将这一总体主题整合到一项研究中。其在慢性和急性淋巴细胞白血病中的作用已在多项临床试验中进行了评估，这些试验是在2022年至2023年期间选取的，以便更好地了解研究最多的单克隆抗体。生物制药化合物伊布替尼、奥妥珠单抗、利妥昔单抗、维奈克拉和奥英妥珠单抗是最近出版物中出现最多的，这表明扩大研究的重要性。所采用的作用机制意味着它们的联合使用在疾病缓解方面更成功，复发率更低，副作用和毒性也更低。除了治疗的副作用和高昂价格外，这些免疫疗法的结果很有前景，提高了生存率，改善了患者的生活质量，并产生了精准医学，旨在实现定制治疗。这种疗法的未来展望包括在公共卫生系统中的应用，患者能够免费接受这种治疗并获得更好的生活质量。
